Status: Recruiting
Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease
In this phase II randomized double-masked clinical trials, subjects with non-resolving corneal epithelial disease/defect (i.e., refractory to standard treatments for at least two weeks) will receive 8 weeks treatment of topical mesenchymal stem cell secretome or vehicle, with continued follow-up for up to Day 70.
Participants needed: 24
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: University of Illinois at ChicagoUpdated: Jan 29, 2026Locations: 1
Eligibility criteria
Age · Patients 18 years of age or older [+7]
Ocular Health [+8]